News
LYPHF
0.395
NaN%
--
Luye Pharma Wins Shareholder Backing for All AGM Resolutions and Capital Mandates
TipRanks · 3d ago
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX)
TipRanks · 06/20 09:01
Luye Pharma’s Novel CNS Drug LY03015 Delivers Strong Phase 2 Data in Tardive Dyskinesia
TipRanks · 06/16 14:41
Luye Pharma Halves 2028 Convertible Bond Float With US$89.74 Million Buyback
TipRanks · 06/11 12:08
Luye Pharma Raises US$180 Million via Premium-Priced 2031 Convertible Bonds
TipRanks · 06/11 00:07
Luye Pharma Wins Vienna MTF Listing Approval for New Bond Issue
TipRanks · 06/08 12:45
Luye Pharma to Swap 2028 Convertible Debt with New 2031 Issue
TipRanks · 06/03 23:08
Luye Pharma Plans Bond Buyback and New USD Convertible Issue
TipRanks · 06/03 13:14
Luye Pharma sets 2026 AGM to renew board, auditor and share issuance mandate
TipRanks · 05/29 14:37
Luye Pharma Starts U.S. PK Bridging Trial for Novel CNS Drug LY03015
TipRanks · 04/20 12:09
Luye Pharma Group (LYPHF) Receives a Buy from SDIC Securities
TipRanks · 04/19 06:15
Luye Pharma Advances Alzheimer’s Psychosis Drug LY03017 Into China Phase II Trial
TipRanks · 04/15 13:07
Luye Pharma Group (LYPHF) Receives a Buy from Citi
TipRanks · 04/15 00:40
Luye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020
TipRanks · 04/08 14:54
Luye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend
TipRanks · 03/31 01:20
Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results
TipRanks · 03/17 13:38
Luye Pharma Completes RMB1.09 Billion Transfer of 25% Stake in Nanjing Luye to NJ Xinshi
TipRanks · 01/26 23:10
Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal
TipRanks · 01/26 23:09
Luye Pharma’s Ruoxinlin NDA for Anxiety Disorder Accepted in China, Targeting Major CNS Market Gap
TipRanks · 01/08 11:09
Luye Pharma Adds Independent Director Xia Lian to Nomination Committee
TipRanks · 12/31/2025 11:10
More
Webull provides a variety of real-time LYPHF stock news. You can receive the latest news about Luye Pharma Grou through multiple platforms. This information may help you make smarter investment decisions.
About LYPHF
Luye Pharma Group Ltd is a company mainly engaged in developing, producing, marketing and selling pharmaceutical products. The Company operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.